Multiple Myeloma Coverage from Every Angle

Recent News

COVID-19 and Myeloma: Continuity of Care in Italian Tertiary Hospital
DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma
FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Ongoing Phase III Trial Compares Venetoclax With Standard Therapy for Resistant Myeloma
Vaccinating Against Pneumonia in Patients With Myeloma
AACR COVID-19: Older Patients With Multiple Myeloma at Risk
Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma
AACR COVID-19: Psychosocial Distress Among Patients With Active Myeloma
FDA Advisory Panel Votes in Favor of Approving Belantamab Mafodotin in Myeloma
FDA Accepts Supplemental New Drug Application for Selinexor in Myeloma
EHA25 Virtual: Adding Elotuzumab to Treatment Regimen in Newly Diagnosed Myeloma
FDA New Drug Application Submitted for Triple-Refractory Myeloma Combination Therapy
EHA25 Virtual: Deauville Score Criteria and Minimal Residual Disease in Myeloma
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: Adding Isatuximab to Front-Line Standard of Care in High-Risk Myeloma
BELLINI Trial of Venetoclax-Based Combination Therapy in Resistant Myeloma
EHA25 Virtual: Long-Term Follow-up of Early Treatment of Smoldering Multiple Myeloma
EHA25 Virtual: Maintenance Myeloma Therapy With Ixazomib and Without AutoSCT
EHA25 Virtual: Single-Agent Belantamab Mafodotin in Resistant Myeloma
ASCO20: Update on BCMA-Directed CAR-T Cell Therapy for Resistant Myeloma
EHA25 Virtual: Adding Isatuximab to Carfilzomib and Dexamethasone in Resistant Myeloma
ASCO20: Update on Orvacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
EHA25 Virtual: BELLINI Trial Update on Venetoclax-Based Regimen in Multiple Myeloma
ASCO20: Long-Term Outcomes With AutoHCT in Multiple Myeloma
ASCO20: Adding Elotuzumab to Bortezomib-Based Therapies for High-Risk Multiple Myeloma
ASCO20: Venetoclax Combination Therapy for Resistant Myeloma
ASCO20: Selinexor-Based Combination Therapy for Resistant Multiple Myeloma
ASCO20: Carfilzomib Versus Bortezomib in Newly Diagnosed Myeloma
Novel Antibody-Drug Conjugate Under Study in Resistant Multiple Myeloma
Biologic Therapies for Patient With Both Multiple Myeloma and Lung Cancer
COVID-19 and Multiple Myeloma: 60-Year-Old Man Successfully Treated With Tocilizumab
Combined Presence of Myeloma and Kidney Cancer: Two Clinical Cases
Using Treatment-Free Interval to Assess Response to Multiple Myeloma Therapy
Daratumumab and Hyaluronidase-fihj Approved by FDA for Multiple Myeloma
Recommendations for Treating Multiple Myeloma During COVID-19 Pandemic
Treating Older Patients With Multiple Myeloma During the COVID-19 Pandemic
Multidrug/Transplant Protocol for High-Risk Smoldering Myeloma
Novel Immunotherapy for Multiple Myeloma: CAR T Cells Targeting CD229
Successful COVID-19 Treatment Reported in a Patient With Multiple Myeloma
Use of Elotuzuzmab, Panobinostat, and Ixazomib in Multiple Myeloma
Which Patients With Myeloma Benefit From Autologous Stem Cell Transplantation?
Myelomatous Pleural Effusion at Time of Initial Diagnosis of Myeloma: Case Report
New Receptor Protein May Successfully Target Multiple Myeloma Cells
Overall Survival With Daratumumab-Based Regimen in Myeloma
Isatuximab-irfc Combination Therapy for Multiple Myeloma Approved by FDA
Study Sheds Light on Genetic Landscape of Resistant Multiple Myeloma
Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.